Thylacine Bio
Thylacine Bio is developing a Peptide Platform for Infectious Disease with a mission to treat illness, prevent infection, and block transmission of persistent endemic respiratory viruses. Their platform is adaptable for emerging viruses, targeting conserved regions less susceptible to mutation, resulting in potent, self-administered antivirals that are easily distributed. They aim to combat current and future outbreaks by rapidly tuning their platform to new threats.
Industries
Nr. of Employees
small (1-50)
Thylacine Bio
525 71st Street P.O. Box #415221 Miami Beach, FL 33141
Products
Peptide-based antiviral candidates (pipeline)
Pipeline of lipid-conjugated peptide therapeutics designed to treat disease, prevent infection, and block transmission of respiratory viruses; candidates reported to have broad-spectrum activity across related viruses.
Peptide-based antiviral candidates (pipeline)
Pipeline of lipid-conjugated peptide therapeutics designed to treat disease, prevent infection, and block transmission of respiratory viruses; candidates reported to have broad-spectrum activity across related viruses.
Services
Rapid design, synthesis, and preclinical evaluation of peptide antiviral candidates using a sequence-to-candidate workflow; offered via in‑house development and external collaborations.
Rapid design, synthesis, and preclinical evaluation of peptide antiviral candidates using a sequence-to-candidate workflow; offered via in‑house development and external collaborations.
Expertise Areas
- Peptide therapeutics for infectious disease
- Antiviral fusion inhibition
- Preclinical virology and animal transmission models
- Rapid pathogen-sequence-driven candidate design
Key Technologies
- Lipid-conjugated antiviral peptides
- Fusion inhibition targeting viral envelope proteins
- Pathogen sequencing for target identification
- In vitro potency and ex vivo assays
News & Updates
A scientific publication by Tara C. Marcinik, Thomas Kicmal, Matteo Porotto, Amédée des Georges, and Anne Moscona in Science Advances, 2022.
A scientific publication by Katharina S Schmitz, Daryl Greers, Rory D de Vries, Matteo Porotto, Rik L de Swart, and Anne Moscona in mBio, 2022.
A scientific publication by Olivier Reynard, Claudia Gonzalez, Anne Moscona, Laurent Vecellio, Matteo Porotto, and Branka Horvat in Nature Communications, 2022.
A scientific publication by Rory D de Vries, Katharina S. Schmitz, Anne Moscona, and Matteo Porotto in Science, 2021.
A scientific publication by Victor K. Outlaw, Francesca T. Bovier, Anne Moscona, and Matteo Porotto in mBio, 2020.
New Partner
Adipiscing elit, sed do eiusmod tempor.
A scientific publication by Tara C. Marcinik, Thomas Kicmal, Matteo Porotto, Amédée des Georges, and Anne Moscona in Science Advances, 2022.
A scientific publication by Katharina S Schmitz, Daryl Greers, Rory D de Vries, Matteo Porotto, Rik L de Swart, and Anne Moscona in mBio, 2022.
A scientific publication by Olivier Reynard, Claudia Gonzalez, Anne Moscona, Laurent Vecellio, Matteo Porotto, and Branka Horvat in Nature Communications, 2022.
A scientific publication by Rory D de Vries, Katharina S. Schmitz, Anne Moscona, and Matteo Porotto in Science, 2021.
A scientific publication by Victor K. Outlaw, Francesca T. Bovier, Anne Moscona, and Matteo Porotto in mBio, 2020.
New Partner
Adipiscing elit, sed do eiusmod tempor.